Hypothesis

Age‑induced up‑regulation of the ‘gerozyme’ 15‑hydroxyprostaglandin dehydrogenase (15‑PGDH) lowers prostaglandin E2 (PGE2) levels, which in turn activates a histone‑deacetylase (HDAC)‑dependent repressor complex at the HAS2 promoter. This epigenetic silencing reduces high‑molecular‑weight HA synthesis, favoring accumulation of low‑molecular‑weight HA (LMW‑HA) fragments that activate TLR4/MyD88‑cPLA2α signaling and sustain inflammation. Thus, 15‑PGDH links the PGE2‑HA axis to the vicious cycle of HA loss and inflammaging.

Mechanistic Rationale

• PGE2 signaling via EP2/EP4 receptors raises intracellular cAMP, activating PKA, which phosphorylates and inhibits HDAC activity (see [8] for AKG‑mediated NF‑κB suppression as a parallel cAMP‑PKA effect).
• When PGE2 falls due to 15‑PGDH overexpression, HDACs remain active, deacetylating histones at the HAS2 promoter and recruiting DNA methyltransferases, leading to stable transcriptional repression (a mechanism not yet shown for HAS2 but observed for other metabolic genes in senescence).
• Reduced HAS2 shifts HA synthesis toward shorter chains; concurrently, oxidative stress (ROS) or hyaluronidase activity generates LMW‑HA that binds TLR4/MyD88, amplifying NF‑κB and cytokine production (TNFα, IL‑1β, IL‑6) as described in [2] and [3].
• The resulting inflammatory milieu further induces 15‑PGDH expression via NF‑κB, creating a feed‑forward loop.

Testable Predictions

1. In aged human dermal fibroblasts and synovial fibroblasts, pharmacological inhibition or siRNA knock‑down of 15‑PGDH will increase intracellular PGE2, raise HAS2 mRNA and protein levels, and elevate high‑molecular‑weight HA secretion.
2. Restoring PGE2 (via EP2/EP4 agonist) will mimic the effect of 15‑PGDH inhibition on HAS2 expression, whereas HDAC inhibition (e.g., trichostatin A) will rescue HAS2 even when 15‑PGDH is over‑expressed.
3. Conversely, over‑expressing 15‑PGDH in young cells will suppress HAS2, increase LMW‑HA/TLR4 signaling, and elevate cytokine output; this will be blocked by adding a PGE2 analog or an HDAC inhibitor.
4. In vivo, topical or intra‑articular delivery of a selective 15‑PGDH inhibitor (e.g., SW033291) in aged mice will increase dermal HA content, reduce LMW‑HA fragments, lower TLR4‑dependent NF‑κB activation, and improve skin elasticity and cartilage thickness.

Experimental Approach

• In vitro: Culture primary human dermal fibroblasts from young (<30 y) and old (>65 y) donors. Treat with 15‑PGDH siRNA, CRISPRi, or SW033291; measure PGE2 (ELISA), HAS2 qPCR/Western, HA size distribution (HPSEC), LMW‑HA (ELISA using HA‑binding protein), and cytokine secretion (TNFα, IL‑1β, IL‑6). Include EP2/EP4 agonist (butaprost) and HDAC inhibitor controls.
• In vivo: Use aged (18‑month) mice; apply SW033291‑loaded hydrogel to dorsal skin or inject intra‑articularly twice weekly for 4 weeks. Assess HA content (HA‑binding protein staining), LMW‑HA levels, TLR4/MyD88 phosphorylation (Western), NF‑κB nuclear translocation (immunofluorescence), histology (Masson’s trichrome for dermal thickness, Safranin‑O for cartilage), and functional readouts (skin tensile strength, grip‑test for joint mobility).
• Controls: Vehicle‑treated aged mice, young mice +/- inhibitor, and 15‑PGDH over‑expression via AAV in young mice to confirm sufficiency.

Potential Outcomes and Interpretation

• If predictions hold: Demonstrates that 15‑PGDH‑driven PGE2 loss is a upstream epigenetic silencer of HAS2, positioning the gerozyme as a master regulator of HA quality. This would unify the observed HA depletion, LMW‑HA‑mediated inflammation, and cartilage/thin‑skin phenotypes.
• If HAS2 is unchanged despite 15‑PGDH inhibition: Suggests alternative senescence‑linked transcriptional repressors (e.g., p53‑dependent promoters) dominate; focus would shift to mapping those factors.
• If PGE2 rescue fails to raise HAS2: Implies that 15‑PGDH influences HA via non‑PGE2 mechanisms (e.g., direct interaction with HA synthases) and redirects investigation.

Broader Implications

Validating this hypothesis would provide a mechanistic bridge between two longevity‑targeted pathways—PGE2/15‑PGDH (cartilage regeneration) and HA homeostasis—and suggest that dual targeting (15‑PGDH inhibition + HA‑boosting strategies) could synergistically counteract dermal aging and joint degeneration.